(Alliance News) - AstraZeneca PLC and Tokyo-based partner Daiichi Sankyo Co Ltd on Monday announced that their investigational antibody drug conjugate Datopotamab deruxtecan showed positive results in an advanced non-small cell lung cancer trial.
The companies said the conjugate showed "statistically significant improvement for the dual primary endpoint of progression-free survival" when compared to docetaxel, the current standard of care chemotherapy.
However, for the dual primary endpoint of overall survival, data were not mature, but an early trend was observed in favour of the conjugate compared to docetaxel.
Susan Galbraith, executive vice president of AstraZeneca's Oncology research and development unit said: "These first phase III trial results from the datopotamab deruxtecan clinical programme provide compelling evidence for the potential role this TROP2-directed antibody drug conjugate can play in treating patients with lung cancer."
TROP2 is a protein highly expressed in a large majority of lung cancers.
AstraZeneca shares were down 5.1% to 10,702.00 pence each in London on Monday morning, while Daiichi Sankyo shares closed up 0.6% at JPY4,578.00 in Tokyo.
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Astrazeneca (AZN)
